jRCT1030210178已完成不适用
Study to Evaluate the Safety, Tolerability, and plasma hydroxyproline concentration of load of gelatin in the Healthy Adult Subjects
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 主要终点
- Safety endpoints
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Basic Science
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 44age old under（—）
- 性别
- Male
入选标准
- •BMI: 18.5 kg/m2 or more, less than 25.0 kg/m2
排除标准
- •Presence of a psychological, gastrointestinal, hepatic, renal, respiratory, endocrine, hematological, immune, neurological, cardiovascular disease or a congenital metabolic abnormality or other anomaly that may affect this study
结局指标
主要结局
Safety endpoints
Adverse events, Laboratory tests, Vital signs
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Donepezil with Glycopyrrolate or Trospium in Elderly Volunteers1004225810012272Alzheimer's diseasedementiaNL-OMON45462Axovant Sciences Ltd.75
已完成
2 期
Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy VolunteersA (Healthy Volunteers)Healthy CoronavirusY59.9LBCTR2020113522Inovio Pharmaceuticals, Inc.542
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part AChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000115538Enliven Therapeutics, Inc.15
尚未招募
1 期
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part BChronic Myeloid Leukaemia (CML)Parkinson's Disease (PD)Cancer - Leukaemia - Chronic leukaemiaNeurological - Parkinson's diseaseACTRN12624000116527Enliven Therapeutics, Inc.15
进行中（未招募）
1 期
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaMaintenance treatment of schizophrenia in patients currently treated with oral antipsychoticsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2019-000063-24-FRTeva Branded Pharmaceutical Products R&D, Inc.300